PSMA-Targeted Imaging Agent Posluma Approved to Aid in Prostate Cancer Detection
The approval was based on data from the LIGHTHOUSE and SPOTLIGHT clinical trials.
Diagnosis & Disease Information
Transient Benefit in Outcomes Seen With Androgen Suppression + RT for Prostate Cancer
Transient clinically meaningful decline noted in EPIC hormonal and sexual domains with total androgen suppression added to radiation
Second-Generation Antiandrogens Up Risk for Cognitive, Functional Toxic Effects
The increasing number of indications for second-generation antiandrogens may result in a large group of men at risk for toxic effects, according to investigators.
Real-World mCSPC First-Line Treatment Intensification Remains Low
Study findings highlight the need for earlier mCSPC treatment intensification by urologists and oncologists.
The EMBARK Trial: An Interview With Neal D. Shore, MD
The phase 3 EMBARK trial involved more than 200 global sites and had 8 years of follow-up.
Adding ADT to Radiation Does Not Up Survival in Intermediate-Risk Prostate Cancer
NRG 0815 is a “landmark” study investigating the role of short-term androgen deprivation therapy added to modern, dose-escalated radiation to treat intermediate-risk prostate cancer.
Newly Identified Prostate Cancer Subtypes May Respond Differently to Treatment
Researchers say they have identified 4 subtypes of prostate cancer with distinct biological and clinical features, and these subtypes may respond differently to treatment.
Camonsertib-PARP Inhibitor Combos May Meet Unmet Need in Advanced Solid Tumors
Combining camonsertib with PARP inhibitors may be an effective strategy for treating advanced solid tumors, a study suggests.
Enzalutamide Ups Metastasis-Free Survival in nmHSPC
Investigators report results from the phase 3 randomized EMBARK trial.
Transgender Women May Be Underdiagnosed With Prostate Cancer
Findings suggest link to more aggressive disease among estrogen users, but researchers say larger studies needed
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...